Health In Tech Inc (HIT)
NASDAQInformation TechnologySoftware - ApplicationSnapshot 2026-09-04
$0.98-1.93%
Close 2026-09-04 · 1-day change
NASDAQInformation TechnologySoftware - ApplicationSnapshot 2026-09-04
Broken: Primary pillar broken — improve operating income from negative levels: metric not reported.
Health In Tech aims for $45M-$50M revenue in 2026. Revenue grew from $7.5M to $8.8M in Q1. The company works to manage lawsuits and improve profits. Digital health demand is growing, helping HIT’s business.
HIT is losing money and profit fell to -$2.1M in Q1. Lawsuits could hurt the company more. Revenue growth may slow and hurt the turnaround.
The market expects about 75% revenue growth in the next year. Our fair value is near $5.39, reflecting this growth. We see risk from losses and legal issues.
Breaks if: new material negative litigation or regulatory event occurs
Manage ongoing litigation and regulatory matters impacting the company.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity with a focus on technology enhancements. The current thesis state reflects mixed signals from management and recent performance, suggesting caution as the company navigates challenges.
The market appears to price in a justified valuation, indicating that HIT is considered cheap compared to its peers. However, there is an expectations gap, suggesting that the market may be skeptical about the company's ability to meet its growth targets.
Management has reaffirmed revenue guidance, but recent financial performance shows a slight decline year-over-year. The focus on expanding sales distribution and enhancing technology suggests a potential for improvement, but the high-risk environment remains a concern.
The thesis hinges on several factors, including management's ability to maintain guidance, the impact of potential Federal Reserve rate cuts, and the performance of sector leaders like SAP and CRM. Any negative guidance or continued litigation could weigh heavily on the outlook.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company expanded its sales distribution. It also reaffirmed its revenue guidance of $45M-$50M for 2026. However, it missed profit expectations, raising concerns about operating income.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. The company disclosed multiple litigation filings in recent quarters. No financial impact metrics are provided, and the priority remains a persistent focus with limited substantive delivery visible in financials.
“HIT — litigation filed, including Exhibit 99.1, with forward-looking statements and safe harbor provisions.”
“HIT — litigation filed, including Exhibit 99.1, with forward-looking statements and safe harbor provisions.”
“HIT — litigation filed, including Exhibit 99.1, with forward-looking statements and safe harbor provisions.”
Breaks if: operating income stays below -$2.1 million over next year
Breaks if: revenue falls below $45 million in FY26
Maintain full-year 2026 revenue guidance between $45 million and $50 million, targeting 35% to 50% year-over-year growth.
Stated as a priority in 3 of last 3 quarters. Management reaffirmed full-year 2026 revenue guidance of $45 million to $50 million, targeting 35% to 50% year-over-year growth. Actual revenue was $16.8 million in first half 2026 versus $17.3 million in first half 2025, showing slight decline in first half but guidance reflects expected growth in second half. The trajectory is consistent with management's stated growth expectations.
“The Company is reaffirming its full-year 2026 revenue guidance of $45 million to $50 million.”
“We are reiterating our guidance for full-year 2026 revenue of between $45 million and $50 million.”
“Health In Tech today reiterated guidance for 2026 annual revenue ranging between $45 million and $50 million.”
In the next 1 to 3 years, HIT's trajectory will depend on its execution against stated priorities and external economic factors. Not investment advice.